Key Takeaways ANIP stock gained 21% in six months, supported by Q3 beats and higher full-year 2025 sales and EPS guidance.ANI Pharmaceuticals' rare disease segment more than doubled sales, led by strong demand for Cortrophin Gel.ANIP's generics unit grew in 2025 but faces rising competition and pricing pressure heading into late 2025.ANI Pharmaceuticals’ (ANIP) stock has risen 21% in the past six months, all thanks to the encouraging financial performance of the company during the first nine months of 2025. ...